


## PHARMACEUTICAL 2018

## Marker Therapeutics Inc. Rank 334 of 349





## PHARMACEUTICAL 2018

## Marker Therapeutics Inc. Rank 334 of 349

The relative strengths and weaknesses of Marker Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Marker Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 142% points. The greatest weakness of Marker Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 641% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,210%, being 933% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	5,180
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,522
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	681
Property and Equipment	0
Research and Development	5,251
Revenues	0
Selling, General and Administrative Expense	6,412

Output Variable	Value in 1000 USD
Assets	5,180
Liabilities	1,522
Expenses	11,663
Stockholders Equity	3,658
Net Income	-10,982
Comprehensive Net Income	-10,982
Economic Capital Ratio	-1,210%